Global Hospital-Acquired Infection Control Market 2017-2021
About Hospital-Acquired Infection Control
HAIs, which are also called nosocomial infections, refer to a collection of conditions that a patient may develop when being treated in hospitals or other healthcare facilities. Modern healthcare settings use multiple devices to treat patients. These can be breeding grounds for microorganisms, which can have adverse effects on patient health. HAIs have caused a significant cost burden on patients and healthcare facilities.
Technavio’s analysts forecast the global hospital-acquired infection control market to grow at a CAGR of 4.81% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global hospital-acquired infection control market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of HAI products.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Hospital-Acquired Infection Control Market 2017-2021
Technavio recognizes the following companies as the key players in the global hospital-acquired infection control market: AstraZeneca, GlaxoSmithKline, Merck, and Pfizer.
Other Prominent Vendors in the market are: 3M, Abbott Laboratories, AbbVie, Advanced Sterilization Products, Alere, Bayer, BD, bioMérieux, Cepheid, Getinge Group, Hoffmann La-Roche, Synergy Health, and Xenex.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is emergence of innovative techniques to remove biofilms. Biofilm refers to a collective layer of microorganisms that can form on the surface of a medical device or on any other area where a biological activity takes place. These layers attach to both biotic and abiotic surfaces. Hence, they can be found at the sites of HAIs.”
According to the report, one driver in the market is increasing innovative measures to prevent HAIs. With increasingly complex pathogens emerging in healthcare facilities and these microbes developing multiple antibiotic resistance, hospitals must use innovative methods to combat HAIs, which is a significant cost burden on the healthcare systems of countries. For instance, HAI infections cost approximately $35 billion annually in the US. Hence innovative measures are required to reduce the incidence of HAIs. The use of ultraviolet (UV) radiation to systematically disinfect hospitals is an innovative approach to control the prevalence of HAIs.
Further, the report states that one challenge in the market is emergence of antibiotic resistance. Antibiotic resistance refers to a microorganism becoming resistant to multiple antibiotics as it modifies itself when exposed to antimicrobial drugs. Microorganisms that develop resistance to antibiotics are referred to as superbugs. Improper hospital hygiene, unwanted or increased use of antibiotics, and emergence of genetic elements that adapt and enhance bacterial resistance mechanisms are the primary causes of antibiotic resistance.
AstraZeneca, GlaxoSmithKline, Merck, Pfizer, 3M, Abbott Laboratories, AbbVie, Advanced Sterilization Products, Alere, Bayer, BD, bioMérieux, Cepheid, Getinge Group, Hoffmann La-Roche, Synergy Health, and Xenex.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook